Prof Fabrice André speaks to ecancer in an online interview for the virtual ESMO 2020 about the overall survival (OS) results from the phase III SOLAR-1 study evaluating alpelisib plus fulvestrant for HR positive and HER2 negative advanced breast cancer.
He reports that there was a numerical difference on median overall survival of 7.9 months between alpelisib plus fulvestrant compared with placebo plus fulvestrant in patients with P3CA mutation.
Prof André explains that this numerical difference, which was in favour of the experimental arm, was not statistically significant, however some subgroups showed more benefit, suggesting that alpelisib could have a bigger impact.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.